Merck’s Ambitious Plans For Follow-On Biologics
Merck outlined ambitious plans for launching and growing a follow-on biologics business during its annual business briefing Dec. 9
You may also be interested in...
The big pharma has five biosimilars in Phase III development with its partner Samsung Bioepis, and expects to file them for regulatory approval in 2015 and 2016.
SEOUL - Merck & Co. has become a leader in the race to bring a low-cost version of Amgen's rheumatoid arthritis blockbuster Enbrel (etandercept) to the market after gaining rights to a late-stage biosimilar version of the biologic developed by South Korea's Hanwha Chemical Corporation
The addition of the Phase III candidate to its portfolio positions Merck as a leader in the race to launch a low-cost version of a major rheumatoid arthritis drug.